Results of Operations and Financial Condition. On August 4, 2026, Personalis, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchang…

and this Item 7.01, including Exhibit 99.1 of this Current Report in Item 9.01, is “furnished” pursuant to the rules and regulations of the Securities and Exchange Commission (“ SEC ”) and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “ Securities Act ”), except as…

Entry into a Material Definitive Agreement. Agreement and Plan of Merger On July 20, 2026, Personalis, Inc., a Delaware corporation (“ Personalis ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Tempus AI, Inc., a Nevada corporation (“ Tempus ” or “ Parent ”), Aviary Development, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“ Merger Sub I ”) and Toucan Development, LLC, a Nevada limited liability…

Results of Operations and Financial Condition. On May 7, 2026, Personalis, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange…

President — Richard Chen: Richard Chen was promoted to President while retaining his roles as Executive Vice President, R&D, and Chief Medical Officer.

Results of Operations and Financial Condition. On February 26, 2026, Personalis, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Ac…

Results of Operations and Financial Condition. On January 8, 2026, Personalis, Inc. issued a press release announcing certain preliminary financial and operational results for the quarter and fiscal year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18…

Other Events. On November 28, 2025, Personalis, Inc. (the “Company”) filed a prospectus supplement to the prospectus (the “Prospectus Supplement”) included in the Company’s shelf registration statement on Form S-3 (Registration No. 333-276204) (the “Registration Statement”), relating to the offer and sale of up to $100,000,000 of shares of the Company’s common stock (the “Shares”) pursuant to that certain Amended and Restated At-the-Market Sales Agreement, dated December 27, 2024, by and amon…

Results of Operations and Financial Condition. On November 4, 2025, Personalis, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “…

Results of Operations and Financial Condition. On August 5, 2025, Personalis, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchang…

Entry into a Material Definitive Agreement. On July 8, 2025, Personalis, Inc. (the “Company”) and Tempus AI, Inc. (“Tempus”) entered into Amendment No. 4 (the “Amendment”) to the Commercialization and Reference Laboratory Agreement, dated November 25, 2023, by and between the Company (as amended by Amendment No. 1, dated August 16, 2024, Amendment No. 2, dated September 20, 2024, and Amendment No. 3, dated December 13, 2024, the “Tempus Agreement”) pursuant to which the Company authorizes Tem…

Results of Operations and Financial Condition. On May 6, 2025, Personalis, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange…

Results of Operations and Financial Condition. On February 27, 2025, Personalis, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Ac…

Results of Operations and Financial Condition. On January 7, 2025, Personalis, Inc. issued a press release announcing its preliminary revenue results for the quarter and fiscal year ended December 31, 2024, and preliminary cash, cash equivalents and short-term investments balance as of December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, includi…

Other Events. On December 27, 2024, Personalis, Inc. (the “Company”) entered into an Amended and Restated At-the-Market Sales Agreement (the “Amended Sales Agreement”) with Piper Sandler & Co. (“Piper”) and BTIG, LLC (“BTIG”). The Amended Sales Agreement amends and restates the At-the-Market Sales Agreement with BTIG, previously entered into on December 30, 2021, as amended by Amendment No. 1 to the At-the-Market Sales Agreement, dated December 21, 2023, to add Piper as a sales agent (Piper a…

Entry into a Material Definitive Agreement. On December 19, 2024, Personalis, Inc. (the “Company”) entered into an investment agreement (the “Investment Agreement”) with Merck Sharp & Dohme LLC (“Merck”) pursuant to which Merck has agreed to purchase from the Company 14,044,943 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price per share of $3.56, representing the last reported closing price of the Common Stock on The Nasdaq Globa…

The sale and issuance of the Shares is exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act. Merck represented to the Company that it is an “accredited investor” as defined in Rule 501 of the Securities Act and that the Shares are being acquired for investment purposes and not with a view to, or for sale in connection with, any distribution thereof, and appropriate legends will be affixed to any certifi…

Results of Operations and Financial Condition. On November 6, 2024, Personalis, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2024. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “…

Entry into a Material Definitive Agreement. On August 16, 2024, Personalis, Inc. (the “Company”) entered into an investment agreement (the “Investment Agreement”) with Tempus AI, Inc. (“Tempus”) pursuant to which the Company issued and sold 3,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price per share of $5.07, representing the last reported closing price of the Common Stock on The Nasdaq Global Market on August 15, 2024.…

The issuance of the Shares was exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act. Tempus represented to the Company that it is an “accredited investor” as defined in Rule 501 of the Securities Act and that the Shares are being acquired for investment purposes and not with a view to, or for sale in connection with, any distribution thereof, and appropriate legends will be affixed to any certificates f…

Results of Operations and Financial Condition. On August 7, 2024, Personalis, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2024. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchang…

Entry into a Material Definitive Agreement. On June 21, 2024 (the “Effective Date”), Personalis, Inc. (the “Company”) and Foresight Diagnostics, Inc. (“Foresight”) entered into a Settlement and License Agreement (the “S&L Agreement”) pursuant to which the Company and Foresight agreed to settle certain previously disclosed litigation pending in U.S. federal district court (the “Litigation”) and inter-partes review proceedings (the “IPRs”) pending before the U.S. Patent Trial and Appeal Board (…

Results of Operations and Financial Condition. On May 8, 2024, Personalis, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange…

Results of Operations and Financial Condition. On February 28, 2024, Personalis, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Ac…

Results of Operations and Financial Condition. On January 5, 2024, Personalis, Inc. issued a press release announcing its preliminary revenue results for the quarter and fiscal year ended December 31, 2023, and preliminary cash, cash equivalents and short-term investments balance as of December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, includi…